This is a clinical study to evaluate the potential benefits of anti-aging supplement on improvement in quality of life , biological age and other healthy outcome .
- Registration Number
- CTRI/2024/06/068327
- Lead Sponsor
- Dr Chikkalingaiah Siddegowda
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
1. Adult healthy male/females aged 40 to 65 years.
2. Participants with Body Mass Index (BMI) between 18.5 and 35 kg/m2.
3. Participants who are willing to provide written Informed Consent for participating in the study
4. Participants who are able to follow verbal and written study directions.
5. Participants must be able to maintain consistent diet and lifestyle habits throughout the study.
6. Participants must be willing to agree to use effective contraceptive methods while on treatment and for 3 months after the completion of study.
7. Participants willing to administer assigned dietary supplements for 3 months.
1. Participants on current use of prescription or over-the-counter nicotinic acid.
2. Participants using any statin drugs.
3. Participants having used any tobacco product or used a recreational drug in the past 6 months.
4. Participants having abnormal screening laboratory test values or other lab test result(s) that would preclude study participation in the judgment of the investigator.
5. Participants with documented presence of atherosclerotic disease and/or cardiopulmonary disease.
6. Participants with history of drug or alcohol abuse.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1) To assess NAD+ Values in blood <br/ ><br>2) Assessment of Biological Age <br/ ><br>3) Physical Performance is assessed by endurance test measured on six minutes walking test <br/ ><br>4) Change in BMI <br/ ><br>5) Quality of Life Assessment will be done using SF-36 QuestionnaireTimepoint: Baseline to end of study.
- Secondary Outcome Measures
Name Time Method 1) Routine clinical laboratory tests: Haematology, Biochemistry, Lipid Profile, LFT, RFT parameters <br/ ><br>2) Safety will be assessed based on number of adverse events <br/ ><br>3) Tolerability will be assessed based on number of subjects drop out due to drug related adverse eventsTimepoint: Baseline to end of study.